磁性壳聚糖微球的制备及对Cr(Ⅵ)的吸附性能研究

用壳聚糖包埋磁流体,用戊二醛交联制成磁性壳聚糖微球,并用红外光谱表征其结构。用制备的磁性壳聚糖微球吸附Cr(Ⅵ)离子,考察了其对Cr(Ⅵ)离子的吸附性能;探讨了吸附时间、溶液pH值、吸附剂用量、温度、Cr(Ⅵ)起始浓度以及其他离子存在对Cr(Ⅵ)离子去除率的影响。实验结果表明,磁性壳聚糖微球吸附Cr(Ⅵ)离子的最佳条件为:吸附平衡时间40 min,最佳吸附pH值6左右,磁性壳聚糖微球用量10 mg,温度升高有利于提高磁性壳聚糖微球的吸附效率,Cr(Ⅵ)离子起始质量浓度为12μg/mL,无机盐的存在引起磁性壳聚糖微球的吸附性能降低。并且考察了吸附剂的再生性能,实验结果表明磁性壳聚糖微球具有良好的重复使用性。     

磁性壳聚糖-聚丙烯酸微球的制备及表征

壳聚糖通过与丙烯酸接枝共聚制得壳聚糖聚丙烯酸悬浮液,在铁磁流体(Fe3O4)与聚乙二醇(分散剂)存在下通过与戊二醛交联,制备了磁性壳聚糖聚丙烯酸微球。用扫描电镜、红外光谱对合成的高分子微球进行形貌观察和结构表征,并进行了元素分析和磁性能测试,研究了磁性微球对牛血清白蛋白(BSA)的吸附效果。结果表明,合成的磁性微球外表呈球形,粒径为100～400nm;当Fe含量为2.47%时,磁性微球的饱和磁化强度约为1.30emug,磁矫顽力为280Oe,磁化率为2.16×10-4(常温下),属于顺磁性材料;其对BSA有较好的吸附效果,饱和吸附量约为400mgg。     

交联聚丙烯酸固载化氧化β-环糊精的合成及其对尿素的吸附性能

大孔交联聚丙烯酸树脂(D151和D152)用氯化亚砜转化为酰氯后,通过成酯反应固载β-环糊精,再进一步用高碘酸钠氧化,合成出具有环状多醛结构的交联聚丙烯酸固载化氧化β-环糊精。系统研究了反应条件对β-环糊精固载化反应的影响,发现摩尔投料比(—COC1/β-CD)为1.5—1/1、温度80℃、时间24 h为最佳固载反应条件。探讨交联聚丙烯酸固载化氧化β-环糊精对尿素的吸附性能,阐明了吸附时间、溶液中尿素浓度、及介质pH值等对吸附量的影响。在尿素浓度130 mg/dL、吸附时间4h、介质pH 7、温度25℃时,交联聚丙烯酸固载化氧化β-环糊精对尿素呈现出最大吸附量82.13 mg/g。     

交联壳聚糖多孔微球对染料的吸附平衡及吸附动力学分析

研究了交联壳聚糖多孔微球对染料的吸附平衡规律,探讨了染料溶液在不同的初始浓度、pH值及不同吸附剂用量条件下吸附动力学规律及吸附动力学控制机理。结果表明,壳聚糖微球对染料的吸附规律可较好地符合Langmuir吸附等温式,吸附动力学模型可以用表观二级速率方程来描述。     

磁性壳聚糖微球用于酶的固定化研究Ⅱ磁性壳聚糖微球对脲酶的吸附及其酶学性质的研究

本文用磁性壳聚糖作为载体用吸附法对脲酶进行固定化研究。结果表明,磁性壳聚糖对脲酶的固载量与磁性壳聚糖微球的粒径、交联度及酶溶液的离子强度成反比;固定化脲酶和自由酶的最适温度分别为80℃和70℃,固定化脲的最适合pH值变化不大,固定化脲酶和自由酶的米氏常数km分别为0.00546mol/L和0.19mol/L。     

Cu(Ⅱ)印迹壳聚糖交联多孔微球去除水溶液中金属离子

研究了以Cu2+为模板的壳聚糖交联多孔微球(Cu-CSCPM)对溶液中Cu2+的吸附性能,为该材料应用于去除废水、果蔬汁等有毒重金属铜离子提供理论基础。首先制备了Cu2+印迹壳聚糖交联多孔微球,并表征了微球的一些物理化学性质;其次采用静态吸附法研究了该微球对Cu2+的吸附行为。结果发现,制得的微球表面多孔,含有活性-NH2,其含水量为69.59%,树脂骨架密度为1.22g/cm3,孔度值为73.68%,交联度为82.42%。初始浓度为60mmol/L、吸附温度40℃、pH=4.0时,Cu-CSCPM对Cu2+的饱和吸附容量为1.89mmol/g。Cu-CSCPM再生5次对Cu2+仍然具有较高吸附容量。     

疏水性磁性微球的制备及对盐藻的吸附研究

采用疏水性材料制备微米级磁性微球,并应用于对盐藻的吸附分离研究,考察了pH值,吸附作用时间,NaCl浓度以及磁性微球添加量对盐藻吸附的影响.结果显示磁性微球对盐藻的吸附受溶液的离子强度影响较大;pH值在一定范围内对盐藻的吸附有较大影响;延长吸附作用时间和加大磁性微球的添加量可以增加对盐藻的吸附量.通过调节pH和施加机械搅拌,磁性微球上吸附的盐藻可以很好被洗脱下来,磁性微球可以多次重复使用.     

壳聚糖亲和磁性毫微粒的制备及其对蛋白质的吸附性能研究

以壳聚糖为包裹材料包埋自制的磁流体 ,制备了具有核 壳结构的磁性毫微粒 ,并偶联色素配基CibacronBlue 3GA(偶联量 1 4 .5μmol/mL)得到了一种新型亲和磁性毫微粒 .结果表明 ,所得亲和磁性微球具有较窄的粒径分布、形状规整 .以牛血清白蛋白 (BSA)和溶菌酶 (Lys)为目标蛋白 ,考察了该亲和磁性毫微粒的吸附性能 ,发现其对BSA和Lys的吸附量分别为 4和 2 8mg/g,吸附行为满足Langmuir吸附等温式 ,且对时间依赖性小而对溶液离子强度敏感 .     

交联化羟丙基壳聚糖对Cr(Ⅵ)的吸附与结构分析

研究了交联化羟丙基壳聚糖对Cr(Ⅵ)的吸附作用,探讨了溶液的pH值、反应时间、温度、初始浓度等因素对其吸附性能的影响,并且用FTIR、XRD和SEM对吸附前后物质进行了表征与结构分析。实验表明,pH是交联羟丙基壳聚糖吸附Cr(Ⅵ)的主要影响因素。在pH=5时,对Cr(Ⅵ)初始浓度为15mg/L的溶液,可控制温度在20℃左右吸附2h,吸附剂交联羟丙基壳聚糖用量为1g/100mL溶液即能达到满意的吸附效果。吸附后由于交联羟丙基壳聚糖与Cr(Ⅵ)的配位作用使得交联羟丙基壳聚糖的结晶性明显降低;Cr(Ⅵ)的配位使得交联羟丙基壳聚糖的表面形貌发生了改变。     

pH值响应的壳聚糖纳米微球的合成及吸附镍离子研究

本工作于水中简单地合成了生物相容且可生物降解的壳聚糖/聚丙烯酸纳米微球,产物具有优异的水稳定性和单分散性。通过傅里叶变换红外光谱、动态光散射、透射电子显微镜、扫描电子显微镜和zeta电位对所得纳米微球的理化性质进行表征,结果显示壳聚糖纳米微球的表面结构和zeta电位对pH值改变具有响应性。携带丰富官能团的产物微球为装填其它活性材料提供了功能位点,因此,可将该纳米微球用作水中去除镍离子的吸附剂。本文从吸附时间、pH值、温度及起始离子浓度等方面研究了纳米微球的吸附行为,发现壳聚糖微球对镍离子的吸附量可以高达44.41mg/g。此外,吸附等温线遵循Freundlich等式,而其动力学符合拟二级模型。     

液相微萃取-高效液相色谱法快速测定唾液中尼古丁含量

建立了一种以液相微萃取为样品前处理技术,结合高效液相色谱快速、有效测定唾液中尼古丁含量的方法。确定了以磷酸三丁酯为有机溶剂、2 mL 0.05 mol/L KOH调节2 mL样品溶液为给出相,10 mmol/LKH2PO4(pH=3.0)为接收相;搅拌速率为500 r/min,萃取时间为17 min的尼古丁优化萃取条件。方法的线性范围0.1-50 mg/L,相关系数r2=0.9996;检出限为0.05 mg/L(S/N=3);相对标准偏差<5%(n=5);相对回收率为96.3%-102.2%。实验证明该法可用于唾液等生物体液中碱性物质的测定。     

Encapsulation of L-dopa and catechol in bovine serum albumin nanocarrier using desolvation method and their in vitro release studies

In the current study, the interaction between L-dopa and bovine serum albumin (BSA) as well as catechol and BSA is investigated separately. In order to achieve the optimum values for encapsulated efficiency (EE), the content of crosslinker/BSA, organic/aqueous phase, drug/BSA, stirring rate, and pH were closely studied taking the advantage of Taguchi method. Particle characterization was carried out using transmission electron microscopy and dynamic light scattering techniques. The most appropriate catechol and L-dopa nanoparticles in the size range of 100 nm and 65 nm, respectively, and at optimized conditions of drug/BSA = 0.1, pH = 7.4, crosslinker/BSA = 0.084, organic/aqueous phase = 4 and stirring rate 400 rpm were obtained. The most favorable EE (encapsulation efficiency) and LC (loading capacity) for L-dopa and catechol was estimated to be 88.1% and 83.6%, respectively, and the calculated LC% was achieved 93.4% and 89.7% for L-dopa and catechol, respectively. The chromatographic analyses results were also found to be in a good agreement with the obtained data for the calculated EE% and LC% values. in vitro release of loaded drugs from nanoparticles in phosphate-buffered saline (pH = 7.4, incubated at 37 ± 0.5°C under stirring rate of 100 rpm) showed the release of 78% catechol and 89% L-dopa during 480 min and 510 min, respectively.     

高效液相色谱法测定吲哚美辛控释胶囊的血药浓度和生物利用度

采用ＯＤＳ柱,甲醇－稀磷酸溶液（７６２４）为流动相,２６０ｎｍ为检测波长,建立了测定血浆中吲哚美辛浓度的高效液相色谱法,并测定了吲哚美辛控释胶囊炎痛康的血药浓度。结果表明,血浆中吲哚美辛浓度在０．１２５～５．０ｍｇ／Ｌ范围内线性关系良好（ｒ＝０．９９９６）,检测限６２．５μｇ／Ｌ（Ｓ／Ｎ＝３１）,平均回收率为１００．４％,日内和日间ＲＳＤ均小于５％。１１位受试者单剂量口服炎痛康后的相对生物利用度为１０２．３８％。     

Simultaneous micellar electrokinetic chromatography and liquid chromatography of adriblastina and tarabine PFS Their application to some biological fluids

The current work presents analytical procedures for simultaneous determination of tarabine PFS and adriblastina by micellar electrokinetic chromatography (MEKC) and liquid chromatography (LC). For MEKC analysis, separations and identifications were accomplished using uncoated fused-silica capillary with hydrodynamic injections in the presence of 50mM borate/phophate pH 8.7 and 100mM SDS. The migration times of tarabine PFS and adriblastina were found to be 2.70 and 6.40min, respectively. Calibration curves were established for 10-300ng/mL (r=0.998) tarabine PFS and for 8-120microg/mL (r=0.999) adriblastina. For LC analysis, separations were performed on teicoplanin stationary phase with reversed mobile phase containing methanol:buffer pH 4.05 (20:80%, v/v) at 285nm. The retention times of tarabine PFS and adriblastina were 5.18 and 7.20min, respectively. Calibration curves were established for 3-90microg/mL (r=0.998) tarabine PFS and for 10-120microg/mL (r=0.999) adriblastina. Both MEKC and LC methods were applied for the simultaneous determination of analytes in urine samples.     

Stress degradation studies and kinetic determinations of duloxetine enteric-coated pellets by HPLC

A stability-indicating HPLC assay method was developed for the quantitative determination of duloxetine (DLX) in a pharmaceutical dosage form in the presence of its degradation products, and kinetic determinations were evaluated in acid conditions and UV-C radiation exposure. Chromatographic separation was achieved by use of an ACE C18 column (250 x 4.0 mm id, 5 microm particle size). The mobile phase was prepared by mixing aqueous 50 mM potassium phosphate buffer (pH 6.0 containing 0.3% triethylamine) and acetonitrile (60 + 40, v/v). DLX was rapidly degraded in an acid medium and in the presence of hydrogen peroxide and UV-C radiation; it was more stable in alkaline medium. The described method was linear over a range of 4.0-14.0 microg/mL for determination of DLX (r = 0.9998). The precision was demonstrated by the RSD of intraday (0.79-1.07%) and interday (0.85%) studies. The mean recovery was found to be 100.56%. The acid degradation of DLX in 0.1 M HCI solution showed an apparent zero-order kinetics (k = 0.177 microg/mL/min), and the photodegradation demonstrated an apparent first-order kinetics (k = 0.082 microg/mL/min). The developed method was found to be simple, specific, robust, linear, precise, and accurate for the determination of DLX in enteric-coated pellets.     

Hydrophilic and Functionalized Nanographene Oxide Incorporated Faster Dissolving Megestrol Acetate

The aim of this work is to present an approach to enhance the dissolution of progestin medication, megestrol acetate (also known as MEGACE), for improving the dissolution rate and kinetic solubility by incorporating nano graphene oxide (nGO). An antisolvent precipitation process was investigated for nGO-drug composite preparation, where prepared composites showed crystalline properties that were similar to the pure drug but enhanced aqueous dispersibility and colloidal stability. To validate the efficient release profile of composite, in vitro dissolution testing was carried out using United States Pharmacopeia, USP-42 paddle method, with gastric pH (1.4) and intestinal pH (6.5) solutions to mimic in vivo conditions. Pure MA is practically insoluble (2 µg/mL at 37 °C). With the incorporation of nGO, it was possible to dissolve nearly 100% in the assay. With the incorporation of 1.0% of nGO, the time required to dissolve 50% and 80% of drug, namely T₅₀ and T₈₀, decreased from 138.0 min to 27.0 min, and the drug did not dissolve for 97.0 min in gastric media, respectively. Additionally, studies done in intestinal media have revealed T₅₀ did not dissolve for 92.0 min. This work shows promise in incorporating functionalized nanoparticles into the crystal lattice of poorly soluble drugs to improve dissolution rate.     

[Hg(SCN)4]2-对蛋白质的荧光猝灭反应及其分析应用

在pH=1.4~3.4的酸性介质中, [Hg(SCN)4]2-配阴离子可与牛血清白蛋白(BSA)、 γ-球蛋白(γ-G)和血红蛋白(Hb)等蛋白质反应形成复合物, 从而引起蛋白质荧光的猝灭. 荧光猝灭的程度在一定范围内与Hg(Ⅱ)的浓度呈线性关系, 可用于Hg(Ⅱ)的测定. 该方法有较高的灵敏度, 检出限(3σ)分别为4.4 ng/mL(BSA)、 6.5 ng/mL(γ-G)和12.9 ng/mL(Hb), 其中以BSA体系灵敏度最高. 研究了[Hg(SCN)4]2-与蛋白质相互作用对荧光光谱的影响、 适宜的反应条件和影响因素; 结合吸收光谱的变化、 温度的影响以及某些热力学参数讨论了荧光猝灭反应的机理; 并以[Hg(SCN)4]2--BSA体系为例考察了共存物质的影响. 结果表明, 该方法具有良好的选择性. 以BSA为探针采用荧光猝灭法测定了红药水中汞溴红和乙肝疫苗中硫柳汞的含量, 结果令人满意.     

Simultaneous separation and determination of Tarabine PFS and Adriblastine using micellar electrokinetic chromatography and high performance liquid chromatography. Application to some biological fluids

The simultaneous determination of Tarabine PFS and Adriblastine by two independent techniques, viz. micellar electrokinetic chromatography (MEKC) and high performance liquid chromatography (HPLC), has been studied. For MEKC analysis, separations and identifications were accomplished using uncoated fused-silica capillaries and injections were performed in the hydrodynamic mode. The running buffer consisted of 0.05 M borate/phosphate pH 8.70, with 0.10 M SDS at an operating voltage of 15.0 kV and the temperature held at 25.0 degrees C. Under these conditions, the migration times of Tarabine PFS and Adriblastine were 2.70 and 6.40 min, respectively. Calibration curves were established for 0.010-0.300 microg/mL (r = 0.99) Tarabine PFS and 8.000-120.0 microg/mL (r = 0.99) Adriblastine. The limit of detection (LOD) was estimated and found to be 0.003 and 3.000 microg/mL of Tarabine PFS and Adriblastine, respectively. The limit of quantitation (LOQ) was found to be 0.009 and 8.000 microg/mL of Tarabine PFS and Adriblastine, respectively. For HPLC analysis, separations and determinations were performed on teicoplanin stationary phase with reversed mobile phase containing methanol:buffer pH 4.05 (20.0:80.0%, v/v) at 285 nm. Calibration curves were established for 3.000-90.00 microg/mL (r = 0.99) Tarabine PFS and for 10.00-120.0 microg/mL (r = 0.99) Adriblastine. LOD and LOQ were estimated and found to be 0.950 and 2.050 microg/mL of Tarabine PFS and 3.130 and 9.250 microg/mL of Adriblastine, respectively. Both MEKC and HPLC methods were applied for the simultaneous determination of analytes in urine samples. It was found that 8.00-10.0% (Tarabine PFS) and 13.0-15.0% (Adriblastine) of the injected dose was recovered in urine samples with 99.5-102% recovery.     

Stability indicating LC method to determination of sodium montelukast in pharmaceutical dosage form and its photodegradation kinetics

Reversed-phase high performance liquid chromatography (LC) method is developed for the assay of sodium montelukast in coated tables and its photodegradation kinetics. An isocratic LC separation is performed on a Zorbax XDB C18 column using a mobile phase of acetonitrile-methanol-water (pH 3.8) (75:10:15, v/v/v) at a flow rate of 0.8 mL/min and detection at 280 nm. The detector response for sodium montelukast is linear over the concentration range from 5-35 μg/mL (r = 0.9999). The specificity of the method is proved using stress conditions. The solutions are exposed to UV radiation (352 nm), alkaline and acid hydrolysis, oxidation, and temperature (80 °C). The intra- and inter-day precision show suitable results (RSD < 0.49%). The accuracy of analytical method is 100.04% (RSD = 0.44%). Detection and quantification limits are 0.10 and 0.32 μg/mL respectively. The robustness of the method is assured after small changes in chromatographic conditions. The kinetic of photodegradation using a LC method is established and it can be described by zero-order kinetics. This developed method show to be viable for the determination of sodium montelukast in pharmaceutical dosage form and satisfactory in the determination of the kinetics of degradation.     

Identification and determination of active anthraquinones in Chinese teas by micellar electrokinetic capillary chromatography

The simultaneous determination of emodin, aloe-emodin and rhein, in Semen Cassiae, Qinghai Wild Dahuang tea, Ningxia Juemingzi tea, Lanzhou Juemingzi tea and Surong Juemingzi tea, has been investigated by micellar electrokinetic capillary chromatography for the fi rst time. With an electrolyte containing 15 mm borax, 30 mm SDS, 10% (v/v) ethanol, at pH 9.60 and 20 kV applied voltage, the three analytes were completely separated within 12 min. The effects of the concentration of borax, electrolyte pH, the concentrations of SDS and organic modifier and the applied voltage on electropheoretic behavior and separation were studied. The linear calibration range was 4-120 micro g/mL (r = 0.9921) for emodin, 10-200 micro g/mL (r = 0.9970) for aloe-emodin and 2-100 micro g/mL (r = 0.9971) for rhein, respectively. Under the optimum conditions, the relative standard deviation (RSD) values (n = 6) of the migration time and the peak area of each peak was 0.59-0.80% and 1.30-3.22%, respectively. The contents of the analytes in Rheum, Qinghai Wild Dahuang tea, Semen Cassiae and three other kinds of teas were easily determined with recoveries ranging from 95.3 to 104.4%.